B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.
B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.